Honasa Consumer acquires 58% of Fluence Pharma at Rs 135 cr EV, launches Honasa Health subsidiary
Mamaearth parent Honasa Consumer is buying a controlling 58% stake in Mumbai-based nutraceuticals brand Fluence Pharma at Rs 135 crore enterprise value, with plans to acquire the remaining 42% over 5-7 years. Fluence becomes the 9th brand in Honasa's portfolio and the first under newly-formed Honasa Health subsidiary.
What happened
Honasa Consumer is acquiring 58% of Mumbai-based nutraceuticals brand Fluence Pharma at Rs 135 crore EV, with plans to buy the rest over 5-7 years. Fluence
Key facts
- 58% stake
- Rs 135 crore EV
- 42% remaining
- 5-7 years
- Rs 195 crore (Reginald Men)
- Rs 4,100 crore (Innovist)
- 9th brand
Why this matters
The phased 58% now / 42% over 5-7 years structure is a replicable template for founder-led D2C tuck-ins—locking in control today while tying out remaining equity to performance and integration milestones.